Gyrus gets US nod for RF (radiofrequency) tonsil treatment:
This article was originally published in Clinica
Gyrus has received US FDA 510(k) marketing clearance to use its Gyrus ENT Somnoplasty system for tonsil reduction in teenagers and adults. The minimally invasive method uses temperature controlled radiofrequency energy to reduce obstructive symptoms in enlarged tonsils. The Reading, UK-based firm already has US clearance to use the system in the treatment of obstructive sleep apnoea, chronic nasal obstruction and habitual snoring. The latest clearance provides another step in broadening the opportunity for the firm in the $1bn head and neck surgery market, says the company.
You may also be interested in...
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.